Author: Ravi Shankar

EXEL Industries
A French Société Anonyme with a share capital of €16,969,750
Registered office: 54, rue Marcel Paul – 51206 Epernay Cedex – France
Reims Companies Register (RCS): No. 095 550 356

Number of shares and voting rights
Article 223-16 of the AMF regulation

Date	Total number of shares comprising the share capital	Total number of voting rights
October 31, 2026	6,787,900	Theoretical voting rights: 9,897,118
		Exercisable voting rights*: 9,890,420

* After deduction of shares without voting rights

Attachment

• EXEL Industries Droits de vote 2026.10.31_EN

10 November 2026

REVEILLE RESOURCES PLC

(“Reveille”, or the “Company”)

Exercise of Warrants

Total Voting Rights

Reveille [AQSE: REV; OTCID: RVREF], a uranium exploration and development company with a primary focus on Italy’s largest uranium deposits, announces that it has received notice for the exercise of warrants in respect of 955,949 new ordinary shares of 1 pence each in the capital of the Company (“Ordinary Shares”) at an exercise price of 10 pence per share, raising gross proceeds of £95,594.90 for the Company (the “Warrant Shares”).

Admission to Trading and Total Voting Rights

Application will be made for the Warrant Shares to be admitted to trading on the Aquis Growth Market (“Admission”). It is anticipated that Admission will occur on or around 13 November 2026.

From Admission, the Company’s issued ordinary share capital will comprise of 83,755,465 Ordinary Shares, with one voting right per Ordinary Share. The Company does not hold any Ordinary Shares in Treasury. Therefore, from Admission, the total number of Ordinary Shares and voting rights in the Company will be 83,755,465.

From Admission, the above figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in the share capital of the Company, under the FCA’s Disclosure Guidance and Transparency Rules.

– ENDS –

For more information, please visit: www.reveille-resources.com or contact the following:

Reveille Resources Plc Ippolito Ingo Cattaneo, Executive Director	info@reveille-resources.com
Allenby Capital Limited, Aquis Corporate Advisor Nick Harriss / Ashur Joseph / Nick Naylor	Tel: +44 (0) 20 3328 5658
Community, Financial PR Italy Pasquo Cicchini / Virginia Giussani	Tel. +39 02 89404231

Notes to Editors

Reveille Resources plc (AQSE: REV; OTCID: RVREF) is a UK natural resources exploration and development company with a primary focus on Italy, where it is advancing the exploration and development of the country’s largest historic uranium deposits.

Through its Italian subsidiary, Futuro Energetico Italiano S.r.l, the Company has submitted exploration-licence applications in respect of the Novazza and Val Vedello uranium projects in northern Italy, each of which is subject to the applicable environmental-assessment process. The projects were historically explored and developed by AGIP Nucleare S.p.A. and its operating subsidiary, SOMIREN, both part of the ENI group, during Italy’s national nuclear programme between 1959 and 1983. This work included more than 87,000 metres of historical drilling and approximately 17 kilometres of underground development.

Reveille’s strategy is to identify and advance uranium projects that have benefited from substantial historical exploration and technical work, but where value has yet to be fully realised due to geopolitical, technological, financial or historical factors. By applying modern exploration techniques and internationally recognised reporting standards, the Company intends to verify historical data, advance exploration and work towards the delineation of mineral resources in accordance with internationally recognised reporting standards.

While Italy remains the Company’s principal area of focus, Reveille will selectively evaluate additional uranium opportunities elsewhere in Europe and in other Western jurisdictions where similar value creation opportunities exist. The Company is committed to advancing its projects responsibly, working closely with local communities, regulators and other stakeholders to ensure that exploration activities are undertaken to the highest environmental, technical and governance standards.

• At Week 16, 69% of participants receiving brepocitinib 45 mg achieved “Clear” or “Almost Clear” skin, with at least a 2-category improvement, compared with 0% receiving placebo
• Improvements in skin disease activity were evident as early as Week 4, increased over time, and were accompanied by benefits on skin-related quality of life
• Brepocitinib was well tolerated during the 16-week study period, with no serious adverse events (SAEs)
• Findings support ongoing Phase 3 BEACON+ study in cutaneous sarcoidosis; topline data expected in calendar year 2028
• Results of the study will be shared by Dr. Misha Rosenbach, MD, in an oral presentation at ACR Convergence 2026 today, November 10

DURHAM, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) — Priovant Therapeutics today announced the publication in JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized, double-blind, placebo-controlled trial evaluating oral brepocitinib in adults with cutaneous sarcoidosis (CS). The publication describes improvements in skin disease activity and skin-related quality of life over 16 weeks of treatment, with 69.2% of participants receiving brepocitinib 45 mg once daily achieving “Clear” or “Almost Clear” skin with at least a 2-category improvement, compared with none of the participants receiving placebo (P = 0.0047).

CS is an inflammatory granulomatous skin disease affecting approximately 40,000 adults in the United States. The condition disproportionately impacts Black Americans, and unlike most inflammatory skin diseases, can rapidly cause permanent scarring and destruction of bone, cartilage, and hair follicles. Despite this significant unmet therapeutic need, there are currently no FDA-approved therapies for CS.

“Cutaneous sarcoidosis is often on the face and severely impacts patients, and there are no approved treatments,” said Dr. Misha Rosenbach, MD, Professor of Dermatology and Rheumatology and Director of the Cutaneous Sarcoidosis Program at the Hospital of the University of Pennsylvania. “This is the largest study in skin sarcoidosis to date, and the result were striking – seeing clear or almost clear skin in more than two-thirds of patients on brepocitinib demonstrates dramatic improvement and was backed by multiple metrics showing this improved patients’ symptoms and quality of life. These published findings bring rigorous clinical evidence to a historically neglected disease and patient population and offer a compelling reason to believe that a fundamentally different future with more targeted, effective treatments may be possible for our patients.”

The publication, “Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis: A Phase 2 Randomized Clinical Trial,” reports results from the Phase 2 dose-ranging portion of BEACON. Thirty-one adults were randomized to brepocitinib 45 mg (n=13), brepocitinib 15 mg (n=11), or placebo (n=7), administered once daily, for 16 weeks of double-blinded treatment.

Both brepocitinib doses demonstrated improvement on the primary endpoint, change from baseline in the Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity (CSAMI-A) score at Week 16. Mean reductions were 22.3 points with 45 mg and 22.2 points with 15 mg, compared with 0.7 points with placebo (P<0.0001 for each comparison). Improvements were evident by Week 4 and increased through Week 16. Across increasingly stringent responder-based and cutaneous remission-oriented endpoints, efficacy consistently favored brepocitinib 45 mg, supporting a dose-dependent treatment effect.

Additional Week 16 findings for brepocitinib 45 mg included:

• Clear or Almost Clear skin: 69.2% achieved a Cutaneous Sarcoidosis Activity-Investigator Global Assessment score of “Clear” or “Almost Clear,” with at least a two-category improvement, compared with 0% on placebo.
• At least 50% improvement in skin disease activity: 76.9% achieved a reduction of at least 50% in CSAMI-A, compared with 0% on placebo.
• At least a 10-point improvement in CSAMI-A: 100% achieved a reduction of at least 10 points in CSAMI-A, compared with 14.3% on placebo.
• Low residual skin disease activity: 61.5% achieved a CSAMI-A score less than 5, compared with 0% on placebo.

Participants receiving brepocitinib 45 mg also reported improvements in skin-related quality of life. Mean improvement on Skindex-16 was 23.5 points, compared with an 8.9-point worsening on placebo. All participants receiving brepocitinib 45 mg reported improvement on the Patient Global Impression of Change, compared with 29% receiving placebo. Post hoc analyses also suggested dose-dependent benefit in participants with lupus pernio, a particularly difficult-to-treat form of CS.

Brepocitinib was well tolerated during the study treatment period, with no serious adverse events (SAEs).

Priovant is evaluating brepocitinib 45 mg once daily for CS in the ongoing Phase 3 portion of the BEACON study (BEACON+). Topline data from BEACON+ is expected in calendar year 2028.

About BEACON +

BEACON+ is the Phase 3 portion of the BEACON trial evaluating brepocitinib in patients with cutaneous sarcoidosis. BEACON+ is enrolling approximately 140 patients with cutaneous sarcoidosis across ~70 sites globally. Patients will be randomized 3:2 between brepocitinib 45mg once daily and placebo. The primary endpoint is the proportion of patients achieving a 50% or greater reduction in the Cutaneous Sarcoidosis Activity and Morphology Instrument – Activity Score (CSAMI-A) at Week 16. Topline data from the BEACON+ study is expected in calendar year 2028.

About Priovant

Priovant Therapeutics is a biotechnology company dedicated to developing and commercializing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company’s commercial product, LISRAYA™ (brepocitinib), is the first and only targeted oral therapy approved for the treatment of adults with dermatomyositis. See important LISRAYA safety information, including boxed warning, at lisrayahcp.com/pi. Brepocitinib, a first-in-class TYK2/JAK1 inhibitor, recently generated positive Phase 3 data in non-infectious uveitis (NIU). In addition to the phase 3 program in cutaneous sarcoidosis, brepocitinib is also under evaluation in a Phase 2b/3 program in lichen planopilaris. These potential indications have not been approved by the FDA. Priovant Therapeutics is a Roivant (Nasdaq: ROIV) company.

Contact

Stephanie Lee: stephanie.lee@priovant.com

VANCOUVER, British Columbia, Nov. 10, 2026 (GLOBE NEWSWIRE) — Centauri Minerals Inc. (TSX-V: CENT) (OTCQX: CNTIF (“Centauri” or the “Company”) is pleased to provide a field update from recent exploration activities at its 100%-owned exploration portfolio projects in Northern Argentina. The current Phase 1 exploration drilling program at the Rio Grande gold-copper project (“Rio Grande”) is the top priority for Centauri (see October 13, 2026 news release), but with the mandate for more new discovery opportunities, the exploration team has also commenced select activities for new drill target generation within Centauri’s greater 40,000-hectare project portfolio.

Highlights:

• Aguas Calientes project (gold and silver in Jujuy) – completion of a NS-AMT and gradient IP-resistivity geophysical survey over an area containing 6 km of well-mineralized float boulders, with goal of identifying drill targets for 2027.
• Frontera project (silver and gold in Catamarca) – meeting with Minister of Mining of Catamarca government and initiated exploration restart process.
• Catua project (copper oxides in Jujuy) – first field visit by new exploration team and renewal of environmental permits for future work.
• Exploration team additions are supporting ramp-up of drilling at Rio Grande as Centauri’s immediate priority, ongoing fieldwork initiatives for new drill targets across the 40,000-ha portfolio, as well as strengthening team to pursue and evaluate potential growth opportunities in Argentina

Sam Leung, Chief Executive Officer and Director of Centauri, commented:

“Beyond the ramp-up of exploration drilling at Rio Grande, Centauri is strategically advancing our prospective portfolio of earlier stage exploration projects in the active Northern Argentina mining region. Centauri’s goal is to efficiently generate new drill targets, not just at Rio Grande, but across the portfolio for new discovery opportunities for our stakeholders. During Q3 and Q4 2026, Centauri expanded its exploration team with the addition of two Salta-based exploration geologists to support the Rio Grande drill program and portfolio-wide target generation. These new portfolio programs and exploration team additions also strengthen Centauri’s presence and commercial advantages in the region for new growth opportunities”.

Completion of Geophysical Program at Aguas Calientes

The Aguas Calientes project is located in Jujuy province, Argentina, approximately 35 km west of the town of San Antonio de los Cobres and in the region of the Aguilar (Grupo Integra) and Pirquitas mines (SSR Mining). In October 2026, Centauri completed a Natural Source Audio-Frequency Magnetotelluric (“NS-AMT”) survey in conjunction with a Gradient Array Induced Polarization (IP) / Resistivity survey. The primary objective of the NSAMT survey is to characterize and map the distribution of the resistivity parameter within the designated project area, from near-surface levels down to depths of approximately 800 m. For the IP, the depth of investigation for resistivity and chargeability parameters is estimated at around 500 m.

Figures 1A and 1B show a summary view of the historical ground magnetics and a geological map of Aguas Calientes. The magenta polygon highlights the Silon zone, where the NS-AMT & IP geophysical survey has been completed. New dataset review and drill target generation work is ongoing, towards a potentially new drill program in 2027.

The geophysical program completed at Aguas Calientes was supported by the community of Puesto Sey in Jujuy province, which provided accommodation and catering to the field team, in line with Centauri’s commitment to local procurement and community partnership.

Environmental Compliance, Field Work at Catua & Plans for Frontera

As a new company, Centauri continues to maintain environmental compliance for its exploration projects in Jujuy Province. In September 2026, the Company completed environmental participatory monitoring campaigns at the Aguas Calientes and Catua projects, and the renewal of the environmental permits (IIA) for both projects is in progress.

An initial site visit was conducted at the Catua project, where rocks from open trenches and surrounding outcrops were observed. There are small levels of sedimentary breccias, poorly exposed in the southern and western parts of the property. Copper mineralization on the property consists of copper coatings (patinas) on clasts in addition to a variety of copper oxides, including malachite, azurite, and chrysocolla as cement in conglomerates and poorly exposed sedimentary breccias. To date, no hypogene sulphide mineralization has been identified in the clasts described in the mineralized sedimentary units. The copper is interpreted to be either exotic (transported by low-temperature fluids) or sedimentary ‘red bed’ style. The Catua project remains at an early stage of exploration, and the team is reviewing the data to assess its potential.

At the Frontera project in Catamarca province, Centauri is updating the project’s environmental permitting to align with the Company’s planned exploration program. The updated submission is being prepared with the Company’s environmental consultant and is expected to be submitted in the fourth quarter of 2026. In October 2026, Centauri representatives met with the Minister of Mining of Catamarca province to introduce Centauri, begin a working relationship with the provincial government, and advance the reactivation of exploration at the Frontera project.

The Frontera project is located close to the national border with Chile and has notable historical trench samples by previous owners that date back over 20 years. Highlights of the historical trench sampling include 8 m of 2,450.0 g/t Ag in the Gallega Zone, 50 m of 312.5 g/t Ag in the Central Zone, and 24 m of 208.0 g/t Ag and 22 m of 0.58 g/t Au in the Ixchel Zone. Limited drilling by previous owners in 2006–2007 intersected mineralization at depth, including 18 m of 0.59 g/t Au and 34.3 g/t Ag from 153 m in hole LFD-001 (including 4 m of 1.63 g/t Au and 385.5 g/t Ag from 167 m) and 5 m of 0.99 g/t Au and 52.6 g/t Ag from 48 m in hole LFD-008. Please visit the Centauri website and corporate presentation for additional information on the Frontera project.

Qualified Person

The scientific and technical data contained in this news release has been reviewed and approved by Dr. Kevin B. Heather, B.Sc. (Hons), M.Sc, Ph.D, FAusIMM, FGS, Technical Advisor to Centauri Minerals, who serves as the qualified person (QP) under the definitions of National Instrument 43-101.

ON BEHALF OF THE CENTAURI BOARD

(signed) “Sam Leung”

Sam Leung, Chief Executive Officer and Director
Phone: +1 (416) 206-4187
Email: sam.leung@centauriminerals.com

Please visit the Centauri website and subscribe to the Centauri news list at www.centauriminerals.com.

About Centauri Minerals Inc.

Centauri Minerals Inc. is a mineral exploration company focused on Northern Argentina, a mining region of increasing global significance. Centauri holds a 100%-interest in a portfolio of exploration projects spanning approximately 40,000 hectares in the provinces of Salta, Jujuy, and Catamarca, which was spun-out from Aldebaran Resources Inc. The most advanced is the Rio Grande gold-copper project located in Salta, which has an independent National Instrument 43-101 compliant mineral resource estimate that highlights significant gold, copper and silver quantities. Centauri has offices and facilities in Salta, Argentina and Vancouver, Canada. Centauri trades on the TSX Venture Exchange with the symbol: CENT and on the OTCQX with the symbol: CNTIF.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain statements regarding Centauri, including management’s assessment of future-plans and operations, may constitute forward-looking statements under applicable securities laws and necessarily involve known and unknown risks and uncertainties, most of which are beyond the control of Centauri. Often, but not always, forward-looking statements or information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate” or “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

Specifically, and without limitation, all statements included in this press release that address activities, events or developments that Centauri expects or anticipates will or may occur in the future, including, but not limited to the proposed exploration and development of the Company’s projects described herein, and management’s assessment of future plans and operations and statements with respect to the completion of the anticipated exploration and development programs, may constitute forward-looking statements under applicable securities laws and necessarily involve known and unknown risks and uncertainties, most of which are beyond Centauri’s control. These risks may cause actual financial and operating results, performance, levels of activity and achievements to differ materially from those expressed in, or implied by, such forward-looking statements. Although Centauri believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The forward-looking statements contained in this press release are made as of the date hereof and Centauri does not undertake any obligation to publicly update or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities law. 

Figure 1A: historical ground magnetics of Aguas Calientes project

Figure 1B: historical geology map of Aguas Calientes project

Figure C: GRAD-IP and NSAMT. Location map of the proposed configuration for the GRAD-IP and NSAMT survey, over a satellite image (Google Earth)

Photo 2a, b and c: Showing a historical open trench with presence of copper oxides mineralization at the Catua Project

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/44355e84-0579-4e72-82c9-f5fe1af5b15e
https://www.globenewswire.com/NewsRoom/AttachmentNg/1a09e6c2-a072-4393-bc3a-8e536d5365d1
https://www.globenewswire.com/NewsRoom/AttachmentNg/544f830b-dad9-4e31-b5eb-25fa8e7651be
https://www.globenewswire.com/NewsRoom/AttachmentNg/6aaf1021-46c6-4b9c-b1e4-a0bb917e262e

BEDFORD, Texas, Nov. 10, 2026 (GLOBE NEWSWIRE) — Legacy Housing Corporation (“Legacy” or the “Company,” NASDAQ: LEGH) announced that Darren McCallon has joined the Company as Chief Financial Officer (“CFO”).

Kenneth E. Shipley, Chairman and Chief Executive Officer, commented, “I am excited for Darren to join our team as Chief Financial Officer. He is a proven CFO and brings a wealth of experience in financial reporting, accounting operations, capital planning, and strategic finance to Legacy. He has held senior leadership positions at public and private companies, and his experience, background, and education will be a great addition to our leadership team.”

Mr. McCallon replaces Jon Langbert, who resumed his retirement on November 6, 2026.

Mr. Shipley continued, “We are incredibly grateful to Jon for pausing his retirement to guide our accounting and finance teams. During his tenure, he provided vital stability, strengthened our financial foundation, and positioned us for long-term success.”

Darren McCallon Bio

Mr. McCallon, age 55, is a seasoned executive with over 25 years of experience in financial reporting, accounting operations, capital planning, M&A, and strategic finance. He has extensive experience with companies in the medical device, staffing, retail, and financial services industries. Since 2023, he has served as Chief Financial Officer of Fortune Insurance, a commercial insurance brokerage firm based in Tacoma, Washington, where he led the company’s successful sale to OneDigital. Previously, he served as Chief Financial Officer of 4WEB Medical, an orthopedic implant company based in Frisco, Texas, from 2014 to 2023, and held senior roles at TrueBlue, Inc. and Blockbuster Inc. Mr. McCallon earned a Bachelor of Business Administration in Finance from the University of Texas at Austin, a Master of Business Administration from Southern Methodist University, and is a Certified Public Accountant.

About Legacy Housing Corporation

Legacy Housing Corporation builds, sells, and finances manufactured homes and “Tiny Houses” distributed through a network of independent retailers and company-owned stores. The Company also sells directly to manufactured housing communities. Legacy is one of the largest producers of manufactured homes in the United States. With current operations focused primarily in the southern United States, we offer our customers an array of quality homes ranging in size from approximately 395 to 2,667 square feet, consisting of 1 to 5 bedrooms, with 1 to 3½ bathrooms. Our homes range in price, at retail, from approximately $47,000 to $200,000.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond our control. As a result, our actual results or performance may differ materially from anticipated results or performance. Legacy undertakes no obligation to update any such forward-looking statements after the date hereof, except as required by law. Investors should not place undue reliance on any such forward-looking statements.

Investor Inquiries:
Darren McCallon, (817) 799-4831
dmccallon@legacyhousingcorp.com

Media Inquiries:
Kira Hovancik, (817) 799-4905
pr@legacyhousingcorp.com

Source: Legacy Housing Corporation

INFORMATION REGARDING THE TOTAL VOTING RIGHTS AND SHARES OF KLÉPIERRE SA AS OF OCTOBER 31, 2026¹

Paris – November 10, 2026

NUMBER OF SHARES AS OF OCTOBER 31, 2026

Date	10/31/2026
Company name	Klépierre
Trading place	Euronext Paris (Compartment A)
Mnemonic	LI
Symbols	EPA:LI / LI:FP / LOIM.PA
ISIN	FR0000121964
Total number of shares	286,861,172
Total number of voting rights
Number of theoretical voting rights2	286,861,172
Number of exercisable voting rights3	286,617,827

AGENDA
February 24, 2027	2026 full-year earnings (after market close)
INVESTOR RELATIONS CONTACTS		MEDIA CONTACTS
Laurent Budd, CFA, Group Head of IR and Financial Communication		Hélène Salmon, Group Head of Communications
+33 (0)6 86 59 74 36	laurent.budd@klepierre.com	+33 (0)6 43 41 97 18	helene.salmon@klepierre.com
Hugo Martins, IR Manager		Marie Gesquière, Taddeo
+33 (0)7 72 11 63 24	hugo.martins@klepierre.com	+33 (0)6 28 22 97 58	teamklepierre@taddeo.fr
Xiaomeng Xiao, IR Manager
+33 (0)6 71 58 88 97	xiaomeng.xiao@klepierre.com
ABOUT KLÉPIERRE
Klépierre is the European leader in shopping malls, with exclusive focus on continental Europe. The Company’s portfolio is valued at €21.8 billion on June 30, 2026, and comprises large shopping centers in more than 10 countries in Continental Europe which together host more than 720 million visitors per year. Klépierre is a French REIT (SIIC) listed on Euronext Paris and is included in the CAC Next 20 and EPRA Euro Zone Indexes. It is also included in ethical indexes, such as CAC SBT 1.5, MSCI Europe ESG Leaders, FTSE4Good, Euronext Vigeo Europe 120, and features in CDP’s A list. These distinctions underscore the Group’s commitment to a proactive sustainable development policy and its global leadership in the fight against climate change.
For more information, please visit the newsroom on our website: www.klepierre.com

---

¹ Provided pursuant to article l. 233-8-II of the French commercial code and article 223-16 of the general regulation of the Autorité des marchés financiers.

²   Theoretical voting rights correspond to the total number of voting rights attached to all shares, including those deprived of voting rights (article 223-11 of the General Regulations of the Autorité des marchés financiers). As of October 31, 2026, Klépierre SA owns 243,345 of its own shares.

³ Exercisable voting rights correspond to the number of voting rights net of shares deprived of voting rights.

Attachment

• PR_NUMBER OF VOTING RIGHTS October 2026

• Patients continuing ianalumab saw further improvement in systemic disease activity through Week 108, with no new safety findings¹
• Nearly two-thirds of patients on continuous ianalumab reached low disease activity at Week 108¹
• Improvements in stimulated salivary flow were maintained in patients with baseline salivary flow >0.4mL/min continuing ianalumab¹
• Patients who switched from placebo to ianalumab monthly saw improvements across most efficacy outcomes, including an increase in low disease activity rates¹
  

Basel, November 10, 2026 – Novartis today presented long-term results from the ongoing NEPTUNUS extension study of ianalumab in Sjögren’s disease at the American College of Rheumatology Convergence 2026. The data showed that the reduction in systemic disease activity continued to deepen from Week 48 through Week 108 among patients who continued ianalumab 300 mg monthly as measured by EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI).¹

Improvements were also sustained in physician- and patient-reported outcomes as well as salivary flow.¹ Additionally, most efficacy outcomes improved after patients switched from placebo to ianalumab.¹ Adverse event and serious adverse event rates were comparable between the two treatment arms through Week 204, with no new safety findings.¹

“Sjögren’s disease is chronic and systemic, requiring treatment options that can provide sustained disease control over the long term,” said Thomas Dörner, Department of Medicine and Clinical Immunology at Charité – Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum Berlin, ein Leibniz-Institut. “These data provide important new insights into long-term treatment response and deepen our understanding of the disease.”

Key findings¹

• At Week 108, ESSDAI reductions continued to deepen with longer ianalumab treatment, with a mean reduction from core-study baseline of 7.5 points in the group that continued ianalumab monthly and 6.5 points in the group that switched from placebo to ianalumab monthly at Week 60.
• Low disease activity (LDA) rates increased from 57.1% to 65.1% in the continuous ianalumab monthly group between Weeks 48 and 108. In patients who switched from placebo to ianalumab monthly at Week 60, LDA rates increased from 50.4% to 60.9%.
• Among patients with stimulated salivary flow greater than 0.4 mL/min at baseline, improvements were maintained through Week 96 in the continuous ianalumab monthly group and observed after patients switched from placebo to ianalumab at Week 60.
• Improvements in physician- and patient-reported measures and symptoms were sustained through Week 108 among patients who continued ianalumab monthly, measured by ESSPRI and SSSD, and were observed following the switch from placebo to ianalumab at Week 60.

Sjögren’s disease is a serious, systemic autoimmune disease in which B-cell dysfunction plays a significant role, contributing to inflammation, tissue damage and symptoms including dryness, fatigue, pain and organ involvement, which can substantially impact patients’ daily lives.^2-6 Targeted therapies are needed to address systemic disease activity, as there are no approved options currently available outside China.⁷

“These findings strengthen the growing body of evidence for ianalumab and reinforce our commitment to advancing a targeted treatment that can improve care for people living with Sjögren’s disease,” said Angelika Jahreis, Global Head, Development, Immunology, Novartis. “The novel dual mechanism of ianalumab is designed to target B-cell dysfunction, which plays a significant role in this complex disease.”

Ianalumab is currently under review by regulatory authorities in multiple countries, including the US where a decision from the Food and Drug Administration is expected this year. The NEPTUNUS-1 and NEPTUNUS-2 studies were the first global Phase III trials to demonstrate a statistically significant reduction in Sjögren’s disease activity.^8,9,10 The NEPTUNUS extension study is ongoing to continue evaluating the longer-term efficacy, safety and tolerability of ianalumab.^1,11

About ianalumab
Ianalumab is a fully human monoclonal antibody with a novel dual mechanism of action that depletes B cells and inhibits their activation and survival via BAFF-R blockade.¹² Novartis is investigating ianalumab for its ability to treat B-cell driven diseases, including Sjögren’s disease, immune thrombocytopenia (ITP), systemic lupus erythematosus (SLE), lupus nephritis (LN), and systemic sclerosis (SSc).^9-11,13-16

About the NEPTUNUS program
NEPTUNUS-1 and NEPTUNUS-2 are global, multicenter, pivotal Phase III trials evaluating the efficacy and safety of ianalumab in people with Sjögren’s disease.^9,10 NEPTUNUS-1 evaluated ianalumab 300 mg subcutaneously (s.c.) monthly versus placebo for 52 weeks, while NEPTUNUS-2 evaluated ianalumab 300 mg s.c. monthly or every three months versus placebo for up to 52 weeks.^9,10 The primary endpoint in both trials assessed improvement in systemic disease activity using ESSDAI. Participants completing the core studies were eligible to enter an ongoing NEPTUNUS extension trial evaluating the long-term efficacy, safety and tolerability of ianalumab.¹¹ The interim analysis of the extension trial includes patients who continued ianalumab and patients who switched from placebo to ianalumab at Week 60.¹

About Sjögren’s disease
Sjögren’s disease is a complex, systemic autoimmune disease that causes inflammation and tissue damage, impacting the entire body.⁵ It primarily affects exocrine glands, leading to excessive dryness, with over 90% of patients experiencing dry eyes and dry mouth.^5,6 The disease is heterogenous and inflicts a wide range of symptoms, with patients most commonly experiencing dryness, fatigue and widespread pain, though 30-40% of patients will also show extraglandular organ involvement.^17,18 The risk of lymphoma is increased in patients with Sjögren’s.¹⁷ Sjögren’s affects approximately 0.25% of the population with an estimated 50% undiagnosed.^19,20 Sjögren’s is nine times more common in women than men.⁵

About Novartis Immunology
At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with complex and often overlooked autoimmune and other immune-mediated diseases, so they can reclaim their lives. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” or similar expressions, or by express or implied discussions regarding: potential new products; potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; or potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; or our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations could be affected by, among other things, uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; the success of our key products, commercial priorities and strategy; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; potential significant breaches of information security or disruptions of our information technology systems; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future global exchange rates; future demand for our products; and other risks and factors referred to in Novartis AG’s most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

1. Dörner T, et al. “Efficacy and Safety of ianalumab in Sjögren’s disease: Long-term results from the NEPTUNUS extension study.” Presented at: American College of Rheumatology Convergence 2026; Late-Breaking Abstract 2535661; Poster Session (LB01-LB18); November 10, 2026.
2. Lee AY, Qi Z, Jackson KJ, et al. Self-reactive B cells are increased in all major stages of peripheral development in Sjögren’s disease. Immunol Cell Biol. 2025;103(4):401-410. doi:10.1111/imcb.70005
3. Both T, Dalm VA, van Hagen PM, et al. Reviewing primary Sjögren’s syndrome: beyond the dryness – From pathophysiology to diagnosis and treatment. Int J Med Sci. 2017;14(3):191-200. doi:10.7150/ijms.17718
4. Cornec D, Devauchelle-Pensec V, Tobón GJ, et al. B cells in Sjögren’s syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun. 2012;39:161-167. doi:10.1016/j.jaut.2012.05.014
5. Negrini S, Emmi G, Greco M, et al. Sjögren’s syndrome: a systemic autoimmune disease. Clin Exp Med. 2022; 22(1):9-25. doi:10.1007/s10238-021-00728-6
6. Maleki-Fischbach M, Kastsianok L, Koslow M, et al. Manifestations and management of Sjögren’s disease. Arthritis Res Ther. 2024; 26(1):43. doi:10.1186/s13075-024-03262-4
7. Novartis. Ianalumab | Sjögren’s disease | Global & US Story House, Version 1.1. September 30, 2026.
8. Grader-Beck T, et al. Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s Disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2). Presented at the American College of Rheumatology (ACR) Congress; October 24-29, 2025; Chicago, Illinois.
9. ClinicalTrials.gov NCT05350072 [Last accessed: November 2026] 
10. ClinicalTrials.gov NCT0539214 [Last accessed: November 2026]
11. ClinicalTrials.gov. NCT05985915 [Last accessed: November 2026]
12. Dörner T, Bowman SJ, Fox R, et al. Safety and efficacy of ianalumab in patients with Sjögren’s disease: 52-week results from a randomized, placebo-controlled, Phase 2b dose-ranging study. Arthritis Rheumatol. 2025; 77(5):560-570. doi:10.1002/art.43059
13. ClinicalTrials.gov NCT05653219 [Last accessed: November 2026] 
14. ClinicalTrials.gov NCT05639114 [Last accessed: November 2026] 
15. ClinicalTrials.gov NCT05126277 [Last accessed: November 2026] 
16. ClinicalTrials.gov NCT06470048 [Last accessed: November 2026]
17. Mariette X, Criswell LA. Primary Sjögren’s Syndrome. N Engl J Med. 2018;378(10):931-939. doi:10.1056/NEJMcp1702514
18. Gairy K, Knight C, Anthony P, et al. Burden of illness among subgroups of patients with primary Sjögren’s syndrome and systemic involvement. Rheumatology (Oxford). 2021;60(4):1871-1881. doi:10.1093/rheumatology/keaa508
19. Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878-1890. doi:10.1016/S0140-6736(23)00457-9
20. Narváez J, Sánchez-Fernández SÁ, Seoane-Mato D, et al. Prevalence of Sjögren’s syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases. Sci Rep. 2020;10(1):10627. doi:10.1038/s41598-020-67462-z

# # #

Novartis Media Relations E-mail: media.relations@novartis.com
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

2

PRESS RELEASE

Luxembourg, 10^th November 2026

BIANNUAL BUYBACK TENDER OFFER

VELCAN HOLDINGS OFFERS TO BUYBACK 100,000 SHARES AT A PRICE OF EUR 14.52 PER SHARE FROM 11 NOVEMBER to 15 DECEMBER 2026

As announced through press release dated 17^th of June 2026, a new statutory biannual liquidity mechanism has been adopted by the Company’s Shareholders’ General Meeting held on 16^th of June 2026.

The new mechanism has been inserted under the article 7.5 of the Company’s bylaws accordingly, to provide liquidity to shareholders who are willing to sell their shares and may be unable to do so in the stock market. Share buybacks are now to be conducted exclusively through bi-annual buyback offers outside the market (Over The Counter) in May-June and November-December every year. Under this procedure, twice a year, the Company offers to buyback between 100,000 and 500,000 shares at a purchase price equal to the revalued net asset value per share, discounted by 49% to 54%. The Board is empowered to decide the number of shares offered to be bought back and the exact discount, within these ranges.

The first biannual offer has been closed on 23^rd July 2026. In compliance with the new mechanism, the Board of directors is launching the second biannual offer, as per which the Company offers to buy 100,000 shares, between the 11^th of November and the 15^th of December 2026, at Eur 14.52 per share. The price per share results from the application of a discount of 51.5%, applied to the revalued net asset value per share as of 31^st of October 2026. The Company’s revalued NAV as of the 31^st of October (Eur 136,456,159) has been divided by the number of outstanding shares, net of the treasury shares (4 558 039 shares).

This offer is made simultaneously to all shareholders. In case more than 100,000 shares are tendered for sale in response to the offer, the number of shares to be purchased from each shareholder will be reduced on a pro rata basis with the total number of shares proposed to be sold by all accepting shareholders.

The next offer will be initiated during the months of May or June 2027.

Shareholders’ willing to sell their shares through this offer can contact their custodians / brokers. Banks and brokers can contact ABN AMRO Bank N.V. (as.exchange.agency@nl.abnamro.com) which is acting as centralizing agent.

All the shares purchased within the framework of this offer will be cancelled and the Company’s share capital will be reduced accordingly.

Offer Calendar

10th of November 2026	Board of Directors’ decision to initiate the share buyback Tender Offer to Shareholders in accordance with the bylaw’s requirements
10th of November 2026	Press release announcing the Tender Offer, and availability to the Shareholders at the Company’s registered office and on the Company’s website of the Tender Offer Document presenting the terms and conditions of the Contractual Buyback Tender Offer.
11th of November 2026	Publication of the press release and the Tender Offer Information Document by the Luxembourg Stock Exchange.
11th of November 2026	Opening of the buyback Tender Offer period.
15th of December 2026	Record Date (5.40 pm CET), being the date and time when participating Shareholders shall have their shares registered under their name in their custodian’s account.
15th of December 2026	Deadline for the participating Shareholders to send their tender orders via their financial intermediaries / custodians to ABN AMRO. Please note that intermediaries may set an earlier deadline to timely communicate the tenders to ABN AMRO.
15th of December 2026	Closing of the buyback Tender Offer period.
18th of December 2026	Publication of a Company’s press release announcing the results of the Tender Offer, including the allocation ratio, if any, in case more than 100,000 shares are tendered to the Tender Offer.
21st of December 2026	Settlement date: Payment against delivery of the shares tendered.
22nd of December 2026	Publication of the operation market notices announcing the results of the operation by the Luxembourg Stock Exchange and Euroclear France.
By 31st March 2027	Share capital reduction by cancellation of all the shares bought back by the Company under the Tender Offer.

Terms capitalized are defined in the Offer Information Document

The complete Offer Information Document is available at:
http://www.velcan.lu/investors/reports-accounts/

* * *

Investor Relations Contact investor@velcan.lu

About Velcan Holdings:

Velcan Holdings is an investment holding company founded in 2005, managing a global portfolio of participations and investments.

The company was launched more than 15 years ago by its reference shareholder LHP SA, owned by Velcan Holdings’ management team.

Velcan Holdings is listed on the unregulated Euro MTF Stock Market in Luxembourg (Ticker VLCN/ISIN FR0010245803). Velcan Holdings never performed any Public Offer as understood under Directive 2003/71/CE of the European Parliament and Council.

Disclaimer

This press release contains prospective information about the potential of the projects in progress and/or of the projects of which the development has begun. This information constitutes objectives attached to projects and shall not be construed as direct or indirect net income forecast of the concerned year. Reader’s attention is also drawn on the fact that the performance of these objectives depends on future circumstances and that it could be affected and/or delayed by risks, known or unknown, uncertainties, and various factors of any nature, notably related to economic, commercial or regulatory conjuncture, which occurrence could be likely to have a negative impact on future activity and performances of the Group.

This announcement does not constitute a public offering (“offre au public”) nor an invitation to the public or to any qualified investor in connection with any offering. This announcement is not an offer of securities in the United States of America or in any other jurisdiction/country.

Attachment

• Velcan Holdings OBRA_PR_10 Novembre 2026

Integration of Advanced AI Tools to Elevate Advisor Experience

ST. LOUIS, Mo. and LAS VEGAS, Nov. 10, 2026 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today announced that it is working with Anthropic to reimagine and enhance the company’s Dashboard platform. The widely used system has long played a critical role in how Stifel financial advisors manage their practices and serve clients. The announcement was made today at Blueprint 2026, Stifel’s annual innovation conference for its financial advisors.

In addition to using Claude, Claude Code, and Claude Design across the firm, the collaboration represents a major step forward in the future of the advisor workspace. Stifel will apply its understanding of advisor workflows with Anthropic’s innovative technology and AI capabilities to modernize the Dashboard experience while preserving the functionality and familiarity that have made it intuitive and popular.

“Our financial advisors are at the center of everything we do,” said Ronald J. Kruszewski, Chairman and Chief Executive Officer of Stifel Financial Corp. “Providing them with exceptional technology is an important part of helping them deliver outstanding service to their clients. Dashboard is a platform our advisors know, value, and have told us they want to see evolve. We are excited to work with Anthropic and leverage its innovation and capabilities to reimagine this important platform for the future. This collaboration reflects our commitment to listening to our advisors, investing in the tools they rely on, and continually improving the technology experience across Stifel.”

“We are working with Stifel to bring the power of Claude to its advisor platform,” said Peter Nolan, Head of Asset and Wealth Management at Anthropic. “This work advances Stifel’s vision of using AI to complement human judgment and helps advisors deliver even greater value to clients.”
 
Stifel serves clients from more than 400 offices across the U.S. with approximately $577 billion in client assets as of September 30, 2026.

Stifel Company Information
Stifel Financial Corp. (NYSE: SF) is a diversified financial services firm providing wealth management, commercial and investment banking, trading, and research services to individuals, institutions, and municipalities. Founded in 1890 and headquartered in St. Louis, Missouri, the firm operates more than 400 offices across the United States and in major global financial centers. As a firm where success meets success, Stifel works closely with individual and institutional clients, aiming to transform opportunities into achievement.

To learn more about Stifel, please visit the Company’s website at Stifel.com. For global disclosures, please visit www.stifel.com/investor-relations/press-releases.

Media Contacts
Neil Shapiro, +1 (212) 271-3447, shapiron@stifel.com
Evan Roesen, +1 (212) 271-3610, roesene@stifel.com

Investor Relations Contact
Joel Jeffrey, +1 (212) 271-3610, investorrelations@stifel.com

THE DISSEMINATION, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IS NOT AUTHORIZED IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER COUNTRY WHERE SUCH COMMUNICATION WOULD VIOLATE APPLICABLE REGULATIONS

Ivry-sur-Seine – France, November 10, 2026, 6:15 PM CET

SUCCESS OF THE TAKEOVER BID INITIATED BY EP GROUP
EP GROUP BECOMES THE CONTROLLING SHAREHOLDER OF FNAC DARTY
WITH 69.3% OF ITS SHARE CAPITAL
REOPENING OF THE OFFER PERIOD FROM NOVEMBER 12 TO NOVEMBER 25, 2026

• Results of the Offer: 40.9% of the share capital of Fnac Darty contributed, bringing EP Group to 69.3% of the share capital of Fnac Darty
• Reopening of the Offer from November 12 to November 25, 2026 (inclusive), giving shareholders and OCEANE holders the opportunity to tender their shares on unchanged terms

The French Financial markets authority (Autorité des marchés financiers – AMF) has published on November 10, 2026 the results of the Tender Offer initiated by EP FR HOLDCo, a company controlled by EP Group, for the outstanding shares and OCEANEs of Fnac Darty (the “Offer”) as well as the Offer reopening schedule.

12,131,427 Fnac Darty shares and 525,798 OCEANEs have been tendered to the Offer which was open from May 12 to November 9, 2026 (inclusive).

In total, based on the number of shares outstanding at October 31, 2026 and taking into account the 28.5% stake already held by its affiliate VESA, EP Group holds, at the end of the initial acceptance period, 20,577,477 shares, representing 69.3 % of the capital and the theoretical voting rights of Fnac Darty. The minimum condition that the offeror, alone or in concert, at the end of the initial acceptance period, hold a number of shares representing a fraction of the capital or voting rights of Fnac Darty in excess of 50% is thus satisfied.

Therefore, and in accordance with the AMF’s General Regulation, the Offer will reopen between November 12, 2026 and November 25, 2026 (inclusive). This reopening will allow shareholders and OCEANEs holders who have not accepted the Offer to do so under unchanged conditions (€35 per share following payment on June 5, 2026 of the €1.0 dividend for the 2025 financial year, and €81.16¹ per OCEANE).

Enrique Martinez, Fnac Darty CEO declared: “I welcome the successful outcome of this offer, which was unanimously recommended by our Board of Directors, as well as the broad support expressed by shareholders for EP Group’s project. We look forward to embarking on the next chapter of Fnac Darty’s history with our new controlling shareholder and to shaping the future of our Group together.”

Daniel Křetínský, Chairman of EP Group, commented: “We are very pleased with the outcome of the Offer and with the confidence placed in us by Fnac Darty shareholders. Becoming the controlling shareholder of Fnac Darty marks an important milestone in our long-term investment in the company. We highly value Fnac Darty’s service-oriented omnichannel proposition, brand heritage and deep retail expertise, as well as leading positions in France, Italy, Belgium and Portugal and a strong and growing presence in Spain and Switzerland. We believe in its long-term potential and are committed to supporting its continued development and look forward to working constructively with the management team led by Enrique Martinez and with all of the company’s stakeholders to support Fnac Darty’s future growth and reinforce its leadership position on a European scale.”

The terms of the reopened Offer remain the same as those set out in the offer document of EP FR HOLDCo which received visa no. 26-128 from the AMF on May 7, 2026.

EP Group has indicated that it does not intend to seek the implementation of a squeeze-out procedure, even if the conditions were satisfied, at the end of the reopening of the Offer.

The documentation linked to the Offer is available on Fnac Darty’s website in the dedicated section (https://www.fnacdarty.com/en/group/investors/projet-doffre-publique-dachat-de-ep-group/) as well as on the AMF website (www.amf-france.org).

Disclaimer
This press release has been prepared for informational purposes only. It does not constitute an offer to buy or a solicitation for the sale of Fnac Darty shares in any country, including France. The dissemination, publication or distribution of this press release may be subject to specific regulations or restrictions in certain countries. Accordingly, persons in possession of this notice are required to inform themselves of any local restrictions that may apply and to comply with them. Fnac Darty excludes any liability in the event of violation of applicable legal restrictions by any person.

About Fnac Darty

Fnac Darty is a European leader in omnichannel retail, a leading player in the sale of consumer electronics, household appliances, cultural and leisure goods. Present in 15 countries, mainly in France, Italy, Belgium, Portugal, Spain and Switzerland, it has nearly 30,000 employees and a multi-format network of around 1,500 stores, with strong positions on the web and a growing number of subscribers to its services. In 2025, the Group recorded sales of more than €10 billion. With Beyond everyday, its strategic plan for 2030, Fnac Darty is continuing its expansion in Europe and deepening its model based on omnichannel, services and circularity.

For more information: www.fnacdarty.com

CONTACTS
ANALYSTS/INVESTORS
Domitille Vielle – Head of Investor Relations – domitille.vielle@fnacdarty.com – +33 (0)6 03 86 05 02
Laura Parisot – Investor Relations Manager – laura.parisot@fnacdarty.com – +33 (0)6 64 74 27 18

PRESS
Bénédicte Debusschere – Head of communications and influence – benedicte.debusschere@fnacdarty.com – +33 (0)6 48 56 70 71

---

1 Based on an interest period starting on March 23, 2026 and ending on November 12, 2026, as settlement date of the initial acceptance period of the Offer.

Attachment

• 20261110_PR_Results intial period OPA_mel